CI

At a glance

ClinicalIndex Comparison Record
Phase 3Not Yet Recruiting· 160 target
Drug / intervention
Venetoclax (VEN) +4 moredrug
Likely dose
Venetoclax (VEN) 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07052422
NCT07052422Phase 3Not Yet Recruiting
CompareCT.gov

Venetoclax+Decitabine+Busulfan+Fludarabine (VEN+DAC+Bu2Flu4) vs Busulfan+Fludarabine Conditioning Regimen (Bu2Flu5 ) for Older Patients With Myeloid Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Nanfang Hospital, Southern Medical University·interventional·Posted Jul 4, 2025·Updated Jul 4, 2025

In Brief

A Phase 3 clinical trial evaluating Venetoclax (VEN), Decitabine (DAC), and 2 other interventions for Older Patients and 3 related conditions. Not yet recruiting, targeting 160 participants.

Detailed Summary

The purpose of this study is to compare the efficacy and safety of venetoclax+decitabine+busulfan+fludarabine (VEN+DAC+Bu2Flu4) regimen with busulfan+fludarabine (Bu2Flu5) regimen in older patients with myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOlder Patients, Myeloid Malignancies, Conditioning, Hematopoietic Stem Cell Transplantation (HSCT)
Countries--
Collaborators--

Timeline

Phase 3Not Yet Recruiting
20262027202820292030
First PostedJul 4, 2025
Enrollment StartJul 15, 2025
Primary CompletionDec 31, 2027
Study CompletionDec 31, 2029
TodayJul 1, 2026
Enrollment to primary: 2.5 yearsPosted 12 months agoPrimary completion in 1.5 years

Interventions

Venetoclax (VEN)drug

Venetoclax (VEN) was administered at 400mg/day on days -10 to -4.

Decitabine (DAC)drug

Decitabine (DAC) was administered at 20mg/m2/day on days -10 to -8.

Busulfan (Bu)drug

Busulfan (Bu) was administered at 3.2 mg/kg/day on days -5 to -4.

Fludarabine (Flu)drug

Fludarabine (Flu) was administered at 30mg/m2/day on days -5 to -2.

Fludarabine (Flu)drug

Fludarabine (Flu) was administered at 30mg/m2/day on days -6 to -2.